Pharma BD Deal Intelligence
Lilly's first move into psychedelic neuroscience; upside gated on 2029 BPL-003 Phase 3 readout
Full analysis, sources & comparables →Eli Lilly agreed to acquire AtaiBeckley Inc., a Nasdaq-listed psychedelic-medicine developer, in a deal announced July 16, 2026. Lilly will pay $6.75 per share in cash (~$2.8B upfront) plus a contingent value right worth up to $2.50 per share tied to development and regulatory milestones, bringing the total potential consideration to approximately $3.8B — the largest psychedelic acquisition to date. The lead asset, BPL-003 (mebufotenin benzoate), is an intranasal synthetic form of 5-MeO-DMT in development for treatment-resistant depression; initial Phase 3 results are expected in 2029. The transaction is subject to customary closing conditions and shareholder approval.
2.8M US cases/yr
Treatment-resistant depression (TRD) is major depressive disorder that fails to respond to at least two adequate courses of antidepressant therapy. A claims-based U.S. analysis (Zhdanava et al., J Clin Psychiatry 2021) estimated ~8.9M adults on medication-treated MDD, of whom ~2.8M (30.9%) meet TRD criteria. TRD carries disproportionate disability, healthcare cost, and suicide risk, and few rapid-acting options exist, leaving a large underserved market.
The only approved rapid-acting TRD-specific therapy is Spravato (esketamine, Janssen), an intranasal NMDA-receptor antagonist; racemic IV ketamine (NMDA antagonist) is used off-label. Auvelity (dextromethorphan-bupropion, Axsome) is an oral NMDA antagonist/sigma-1 agonist approved in MDD. Standard care remains SSRIs/SNRIs with atypical-antipsychotic augmentation (e.g., aripiprazole, a dopamine partial agonist). The leading psychedelic competitor is Compass Pathways' COMP360 (synthetic psilocybin, a 5-HT2A agonist) in Phase 3 with a ~6-8 hour dosing session. BPL-003's synthetic 5-MeO-DMT differentiates on a much shorter (~30-90 minute) in-clinic psychedelic experience, easing clinic throughput.
Beckley Psytech doses the first patient in its international Phase 2b study of BPL-003, a synthetic intranasal 5-MeO-DMT formulation, for treatment-resistant depression.
atai/Beckley Psytech report positive initial Phase 2a data for BPL-003 (intranasal 5-MeO-DMT) in treatment-resistant depression, supporting advancement of the intranasal psychedelic.
atai doses the first patient in Elumina, the Phase 2 trial of VLS-01, an oral transmucosal DMT film, in treatment-resistant depression.
Lilly agrees to acquire AtaiBeckley for $6.75/share cash (~$2.8B upfront) plus contingent value rights of up to $2.50/share tied to three BPL-003 and VLS-01 development/regulatory milestones (up to ~$3.8B total) - the largest psychedelic-medicine acquisition to date.
Lilly's entry validates the TRD psychedelic thesis but the bulk of value sits in the CVR: initial BPL-003 Phase 3 results are expected in early 2029, with VLS-01 topline in Q4 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / AtaiBeckley Inc. (this deal) | 2026 | $3.8B | 61 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |